Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical Co (JP:4536)
:4536
RESEARCH TOOLSreports
Total Valuation
Santen Pharmaceutical Co has a market cap or net worth of ¥483.24B. The enterprise value is ¥510.34B.
Market Cap¥483.24B
Enterprise Value¥510.34B
Share Statistics
Santen Pharmaceutical Co has 342,055,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding342,055,540
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Santen Pharmaceutical Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 9.97%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)9.97%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee80.65M
Profits Per Employee7.13M
Employee Count3,744
Asset Turnover0.69
Inventory Turnover3.20
Valuation Ratios
The current PE Ratio of Santen Pharmaceutical Co is 19.55. Santen Pharmaceutical Co’s PEG ratio is -0.07.
PE Ratio19.55
PS Ratio―
PB Ratio1.70
Price to Fair Value1.70
Price to FCF8.41
Price to Operating Cash Flow7.17
PEG Ratio-0.07
Income Statement
In the last 12 months, Santen Pharmaceutical Co had revenue of 301.96B and earned 26.64B in profits. Earnings per share was 72.62.
Revenue301.96B
Gross Profit163.88B
Operating Income38.54B
Pretax Income29.87B
Net Income26.64B
EBITDA56.46B
Earnings Per Share (EPS)72.62
Cash Flow
In the last 12 months, operating cash flow was 55.25B and capital expenditures -9.60B, giving a free cash flow of 45.64B billion.
Operating Cash Flow55.25B
Free Cash Flow45.64B
Free Cash Flow per Share133.44
Dividends & Yields
Santen Pharmaceutical Co pays an annual dividend of ¥17, resulting in a dividend yield of 2.39%
Dividend Per Share¥17
Dividend Yield2.39%
Payout Ratio17.97%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-3.33%
50-Day Moving Average1.39K
200-Day Moving Average1.61K
Relative Strength Index (RSI)54.70
Average Volume (3m)1.24M
Important Dates
Santen Pharmaceutical Co upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateFeb 6, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Santen Pharmaceutical Co as a current ratio of 2.54, with Debt / Equity ratio of 0.00%
Current Ratio2.54
Quick Ratio2.08
Debt to Market Cap0.06
Net Debt to EBITDA-1.05
Interest Coverage Ratio14.47
Taxes
In the past 12 months, Santen Pharmaceutical Co has paid 3.17B in taxes.
Income Tax3.17B
Effective Tax Rate0.11
Enterprise Valuation
Santen Pharmaceutical Co EV to EBITDA ratio is 8.18, with an EV/FCF ratio of 7.45.
EV to Sales1.53
EV to EBITDA8.18
EV to Free Cash Flow7.45
EV to Operating Cash Flow6.35
Balance Sheet
Santen Pharmaceutical Co has ¥77.85B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of -¥77.85B billion.
Cash & Marketable Securities¥77.85B
Total Debt¥0.00
Net Cash-¥77.85B
Net Cash Per Share-¥227.60
Tangible Book Value Per Share¥603.86
Margins
Gross margin is 55.58%, with operating margin of 12.76%, and net profit margin of 8.82%.
Gross Margin55.58%
Operating Margin12.76%
Pretax Margin9.89%
Net Profit Margin8.82%
EBITDA Margin18.70%
EBIT Margin10.78%
Analyst Forecast
The average price target for Santen Pharmaceutical Co is ¥2,213.18, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥2,213.18
Price Target Upside56.46% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-0.06%
EPS Growth Forecast2.75%